CliffBio
small molecule

CABENUVA KIT

CABOTEGRAVIR; RILPIVIRINE

Loss of exclusivityOctober 2040latest FDA-listed patent expiry
CompanyViiV Healthcare →See this company's full patent-cliff portfolio

Drug detail

Brand nameCABENUVA KIT
Active ingredientCABOTEGRAVIR; RILPIVIRINE
Strength400MG/2ML (200MG/ML);600MG/2ML (300MG/ML)
Dosage formSUSPENSION, EXTENDED RELEASE
RouteINTRAMUSCULAR
ModalitySmall molecule
FDA approvalJanuary 2021
Marketing statusRX

Listed patents

PatentExpiresType
12636285October 2040use U-3348
12636286October 2040use U-3348
12178815July 2038use U-3348
11389448April 2032product
RE50189November 2031use U-3348
11224597September 2031product
12138264September 2031product
8410103February 2031substance, product
11389447June 2027use U-3405
10927129April 2026substance, product

Regulatory exclusivity

CodeExpires
NCEJanuary 2026

More from ViiV Healthcare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

CABENUVA KIT patent cliff — loss of exclusivity October 2040 | CliffBio